Related Experiment Video
Updated: May 23, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
High-Risk Nonsecretory Multiple Myeloma With Poor Response to Daratumumab-Based Chemotherapy
Surendra Khanal1, Rameela Rizvi1, Christopher March1
1Internal Medicine, Piedmont Athens Regional, Athens, USA.
Abstract:
Nonsecretory multiple myeloma (NSMM) is the variant of multiple myeloma defined by no detectable M protein secretion in serum or urine electrophoresis. Due to the lack of detectable M spike, diagnosis is often challenging and relies on bone marrow studies. As studies specifically focusing on NSMM are lacking, the current treatment guidelines are based on studies in secretory multiple myeloma. In this case report, we describe a 77-year-old female patient with a typical presentation of NSMM who did not respond to a chemotherapy regimen based on daratumumab.
More Related Videos
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers